❉ Buffybot wonderful businesses, fair prices

← back

ILMN Illumina, Inc.

pharma · 2026-10-26

N/A
too hard · 43
Owner-earnings value$69.58
Price$269.42
Margin of safety -74.2%

Quality gate · 43/100

Returns on capital 0/30
Consistency 5.5/22
Margins / pricing power 15.8/16
Balance sheet 13.0/16
Cash conversion 3.3/10
Capital allocation 5.5/6

⚠ sub-hurdle returns (median roic -15% < 9%) · unprofitable in too many years

Median ROIC-15.3%
Gross margin66.2%
Net debt / EBITDA0.8x
Share count / yr-1.1%
Profitable years1/4

Moat & management

Owner-earnings inputs

Owner earnings (TTM)962.00M
Owner-earnings yield2.4%
Free-cash-flow yield2.4%
Growth used (normalized)0.0%
Market-implied growth (reverse DCF)25.0%
Terminal growth3.0%
Discount rate (hurdle)11.4%

Projected owner earnings

YrOwner earningsGrowthPV
1962.00M 0.0%863.86M
2965.21M 0.3%778.33M
3971.64M 0.7%703.59M
4981.36M 1.0%638.13M
5994.44M 1.3%580.68M
61.01B 1.7%530.13M
71.03B 2.0%485.57M
81.06B 2.3%446.21M
91.08B 2.7%411.38M
101.12B 3.0%380.50M

⚠ maintenance capex ≈ min(capex, D&A), capped at FCF · Price pays for ~25%/yr owner-earnings growth over 10y (reverse DCF); model credits 0%.

History

DateQualityPriceValueMoSRating
2026-10-26 43 $269.42 $69.58 -74.2% N/A
2026-09-22 43 $238.82 $67.95 -71.5% N/A